1-8 of 8
Ken Mills, PHD
Close
Sort by
Journal Articles

Cellular Aminopeptidase Inhibition as a Target for the Therapy of AML by the Novel Agent CHR 2797.

Christopher Jenkins, MB, BCh, Ken Mills, PHD, Chris Pepper, PHD, Burnett Alan, MB BCh
Journal: Blood
Blood (2007) 110 (11): 1608.
https://doi.org/10.1182/blood.V110.11.1608.1608
Published: 2007
Journal Articles

An International Multi-Center Study To Define the Application of Microarray-Based Gene Expression Profiling in the Diagnosis and Sub-Classification of Leukemia (MILE Study): Analysis of Completed Stage I with 2030 Patients Achieved a 95.4% Accuracy.

Torsten Haferlach, MD, Alexander Kohlmann, PhD, Giuseppe Basso, MD, Marie-Christine Bene, PhD, James R. Downing, MD, Sheilla Shurtleff, PhD, Jesus M. Hernandez, MD, Wolf-Karsten Hofmann, MD, Thomas J. Kipps, MD, PhD, Truus Te Kronnie, PhD, Wei-Min Liu, PhD, Elisabeth MacIntyre, PhD, Ken Mills, PhD, Claude Preudhomme, PhD, Sabina Chiaretti, MD, Laura Z. Rassenti, PhD, John de Vos, PhD, Allen Yeoh, MD, Evelyn Koay, MD, Peter Papenhausen, MD, Mickey Williams, PhD, Lothar Wieczorek, PhD, Robert Foa, MD
Journal: Blood
Blood (2007) 110 (11): 3169.
https://doi.org/10.1182/blood.V110.11.3169.3169
Published: 2007
Journal Articles

PHF23: A Novel Erythropoietin-Induced Gene Associated with AML and MDS.

Vivien M. Hodges, PhD, Susan Rainey, PhD, Victoria Smyth, PhD, Ken Mills, PhD, Terence R.J. Lappin, PhD, A. Peter Maxwell, MD PhD
Journal: Blood
Blood (2007) 110 (11): 3178.
https://doi.org/10.1182/blood.V110.11.3178.3178
Published: 2007
Journal Articles

Deregulation of RARγ and RARγ-Specific miRNAs in AML.

Angela N. Barrett, PhD, Rajeev Gupta, MD, Annegret Glasow, PhD, David Grimwade, PhD, Marieke von Lindern, PhD, Samuel Waxman, MD, Ken Mills, PhD, FRCPath, Alan Burnett, PhD, Tariq Enver, PhD, Arthur Zelent, PhD
Journal: Blood
Blood (2007) 110 (11): 3182.
https://doi.org/10.1182/blood.V110.11.3182.3182
Published: 2007
Journal Articles

An International Multi-Center Study To Define the Application of Microarrays in the Diagnosis and Subclassification of Leukemia (MILE Study): Interim Analysis Based on 1,889 Patients Achieves 95.4% Prediction Accuracy.

Torsten Haferlach, MD, Alexander Kohlmann, PhD, Giuseppe Basso, PhD, Marie-Christine Bene, PhD, James Downing, PhD, Sheilla Shurtleff, PhD, Jesus M. Hernandez, MD, Wolf-Karsten Hofmann, MD, Thomas J. Kipps, PhD, Truus te Kronnie, PhD, Wei-Min Liu, PhD, Rui Li, Elisabeth Macintyre, PhD, Claude Preudhomme, PhD, Sabina Chiaretti, MD, Laura Rassenti, PhD, John de Vos, PhD, Allen Yeoh, MD, Charlotte Brown, PhD, Mickey Williams, PhD, Ken Mills, PhD, Lothar Wieczorek, Robert Foa, PhD
Journal: Blood
Blood (2006) 108 (11): 103.
https://doi.org/10.1182/blood.V108.11.103.103
Published: 2006
Journal Articles

The Novel Anti-Leukemic Agent LC-1, Is Preferentially Cytotoxic in CLL Cells Derived from Poor Prognostic Subsets.

Chris Pepper, PhD, Chris Fegan, MD, Paul Brennan, PhD, Ken Mills, PhD, Alan K. Burnett, MD
Journal: Blood
Blood (2005) 106 (11): 2981.
https://doi.org/10.1182/blood.V106.11.2981.2981
Published: 2005
Journal Articles

RUNX1-RUNX1T1 Induces Over-Expression of γ-Catenin in Human CD34 + Cells, Increasing Self Renewal and Impairing Granulocytic Differentiation.

Alex Tonks, PhD, Lorna Pearn, Megan Musson, Amanda Gilkes, Ken Mills, PhD, Alan Burnett, MD, Richard Darley, PhD
Journal: Blood
Blood (2005) 106 (11): 3003.
https://doi.org/10.1182/blood.V106.11.3003.3003
Published: 2005
Journal Articles

Micro-Array and Protein Analyses Reveal a Preferential Autocrine VEGF Survival Loop in CD38 + Sub-Clones When Compared with CD38 − Sub-Clones Derived from the Same CLL Patient.

Chris Pepper, PhD, Rachel Ward, BSc, Jane Starczynski, PhD, Clare Rowntree, MD, PhD, Guy Pratt, MD, Ken Mills, PhD, Chris Fegan, MD
Journal: Blood
Blood (2005) 106 (11): 180.
https://doi.org/10.1182/blood.V106.11.180.180
Published: 2005